Gilead preps filing for hepatitis D therapy Hepcludex in US

Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug’s safety and efficacy was shown in late-stage clinical trials.